Targeting NETRIN-1 in Sonic Hedgehog dependent Medulloblastoma : a Promising Therapeutic Pathway

A new collaborative work between NETRIS Pharma, Institut Curie and the Cancer Research Center of Lyon, published in Nature Communications underscores the key role of NETRIN-1 in aggressive Sonic Hedgehog dependent medulloblastoma. The study reveals the importance of NETRIN-1 in promoting the cancer cell survival but also in the resistance to the approved Sonic Hedgehog inhibitors. Notably, the use of a NETRIN-1-blocking antibody NP137 as a single agent or in combination with SHH inhibitors results in anti-tumor activity in various animal medulloblastoma models, providing hope of new and safe therapeutic strategy for pediatric cancers. At NETRIS Pharma, we are proud to be developing NP137 — the first monoclonal antibody targeting NETRIN-1 — with ongoing clinical studies exploring its role in reversing resistance to standard therapies. Go to our « Publications » page to read the entire article, or click on the link below : https://rdcu.be/epfgt

The release as fetched from its publisher. netrispharma.com ↗